Prostate Cell News 10.15 May 3, 2019 | |
| |
TOP STORYIn a previous report, the authors characterized the stromal cells derived from prostate cancer specimens. Here, they characterized the epithelial cells isolated from the same tumors. [Int J Cancer] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Upon validation, miR-346, miR-361-3p and miR-197 inhibitors markedly reduced androgen receptor (AR) transcriptional activity, mRNA and protein levels, increased apoptosis, reduced proliferation, repressed EMT, and inhibited prostate cancer migration and invasion, demonstrating additive effects with AR inhibition. [Oncogene] Full Article Loss of Notch1 decreased metastatic potential of prostate cancer cells in invasion assays in vitro as well as in vivo experiments. Moreover, treatment with gamma secretase inhibitors, or Notch1 gene deletion synergized with anti-androgen therapies, Enzalutamide or Abiraterone, to decrease the growth of prostate cancer cells. [Mol Cancer Ther] Abstract Pregnenolone (Preg) and progesterone (Prog) stimulated cell proliferation and androgen receptor target gene expression in VCaP, DuCaP, LNCaP, and their respective castration‐resistant prostate cancer sublines. The antiandrogen RD162, but not CYP17A1 inhibition with TAK700, abiraterone or siRNA, was able to block Preg‐ and Prog‐induced proliferation. [Prostate] Full Article Salinomycin Triggers Endoplasmic Reticulum Stress through ATP2A3 Upregulation in PC-3 Cells Researchers analyzed and identified differentially expressed genes after treatment with or without salinomycin using a gene expression microarray in vitro and in vivo. [BMC Cancer] Full Article Modulation of miR‐34a in Curcumin‐Induced Antiproliferation of Prostate Cancer Cells Scientists showed that curcumin altered the expression of cell cycle‐related genes and inhibited the proliferation of prostate cancer cells. Furthermore, they found that curcumin significantly upregulated the expression of miR‐34a, along with the downregulated expression of β‐catenin and c‐myc in three prostate cancer cell lines. [J Cell Biochem] Abstract The authors found the expression levels of urothelial carcinoma associated 1 (UCA1) was higher in the prostate cancer cell lines PC-3, LnCaP, and DU-145 than in the normal prostate epithelial cell line RWPE-1. Functionally, they found knockdown of UCA1 in PC-3 significantly suppressed cell growth and invasion of PC-3, while overexpression of UCA1 in DU-145 cells promote cell growth and invasion. [Biosci Rep] Full Article Synergistic Effects of Nobiletin and Sorafenib Combination on Metastatic Prostate Cancer Cells Researchers indicated that nobiletin and sorafenib (SOR) combination had a significant inhibitory effect on the viability of PC-3 cells with less toxicity on HUVEC cells than SOR alone. [Nutr Cancer] Abstract Poly(I:C)-Mediated Death of Human Prostate Cancer Cell Lines Is Induced by Interleukin-27 Treatment Using DU145 and PC3 cell lines as models of prostate cancer, scientists investigated whether interleukin (IL)-27 and interferon (IFN)-γ affect toll-like receptor 3-mediated cell death. They demonstrated that when IL-27 or IFN-γ was added with polyinosinic-polycytidylic acid [poly(I:C)], type I IFN expression increased concurrently with cell death. [J Interferon Cytokine Res] Abstract Investigators developed a cell-killing model for two cell populations to predict the surviving fractions, and compared it with the conventional linear-quadratic model. [J Radiat Res] Full Article Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News. | |
| |
REVIEWSThe Hippo Pathway in Prostate Cancer The authors draw on insights learned from other types of cancers and review the latest advances linking the Hippo pathway and Yes-associated protein/PDZ-binding motif to prostate cancer onset and progression. [Cells] Full Article Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSThe Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental New Drug Application to the FDA seeking approval of a new indication for ERLEADA® for the treatment of patients with metastatic castration-sensitive prostate cancer. [Johnson & Johnson Services, Inc.] Press Release US FDA Accepts New Drug Application and Grants Priority Review for Darolutamide Bayer today announced the FDA has accepted the New Drug Application and granted Priority Review to darolutamide for the treatment of non-metastatic castration-resistant prostate cancer. [Bayer AG] Press Release | |
| |
POLICY NEWSGerman Research Promised a Decade of Budget Increases German research organizations cheered a decision announced by state and federal ministers to increase research budgets by 3% a year for the next decade—a total boost of €17 billion over that time. [ScienceInsider] Editorial Senator’s Queries Prompt NIH and NSF to Clarify How They Monitor Foreign Research Ties Responding to the rising concern within Congress that foreign governments are taking advantage of the open US research enterprise, the National Institutes of Health (NIH) and the National Science Foundation (NSF) have recently tweaked their grantmaking process to better monitor the foreign ties of the researchers they fund. [ScienceInsider] Editorial
| |
EVENTSNEW Prostate Cancer 19 (PCa19) Prague Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK) Postdoctoral Research Position – Molecular Biology & Cancer Research (Augusta University) Postdoctoral Fellow – Prostate Cancer Biology (University of Maryland) Postdoctoral Fellow – Cancer Systems Imaging (The University of Texas MD Anderson Cancer Center) Postdoctoral Position – Prostate Cancer (UT Health San Antonio) Postdoctoral Position – Microenvironment & Cancer (Brigham and Women’s Hospital) Postdoctoral Fellow – Prostate Cancer & Stem Cell Biology (City of Hope) Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|